EOS IMAGING EOS imaging subsidiary OneFit Medical's personalized instruments now used in eight countries
Paris, August 11, 2014 - EOS imaging (Euronext Paris, FR0011191766 - EOSI), the pioneer in orthopedic
2D/3D imaging, announced today that usage of its customized, 3D-printed surgical cutting blocks has begun for knee surgeries in Australia. The patient specific cutting blocks, developed and manufactured by EOS imaging subsidiary oneFIT Medical, had been until now used for surgeries in seven European countries.
The 3D cutting blocks engineered by OneFit Medical are designed to match the individual patient's anatomy to help surgeons perform fast, precise knee replacement surgeries. OneFit Medical's cutting blocks are currently developed using MRI and CT images and sold to implant manufacturers, within agreements that include today 20 implant manufacturers. The Company is exploring the development of improved instruments utilizing EOS images.
EOS imaging and OneFit Medical are developing additional EOS-based solutions, such as hipEOS which was granted CE mark last March for hip replacement surgery. hipEOS, the first offering of a software portfolio associated with the EOS imaging system, will be deployed later this year in Europe as an online service to assist surgeons in hip prosthesis selection and placement simulation based on 3D images generated by the EOS system.
Marie Meynadier, CEO of EOS imaging, said, "Building on robust international sales of our EOS imaging system, the consumable product offerings generated by OneFit will provide an additional revenue stream for the Company besides equipment purchases and service fees. We look forward to expanding our OneFit technology with hipEOS software and other future applications."
For more information, please visit www.eos-imaging.com.
EOS imaging designs, develops, and markets EOS®, a patented medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 10 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December
31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38
engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal
(Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris ISIN: FR0011191766 - Ticker: EOSI Next press release: 2014 half-year results on September 1st, 2014 (after market).Contacts: | ||
Anne Renevot | NewCap | The Ruth Group (US) |
CFO | Financial communication and investor relations | Press relations |
Tel.: +33 (0)1 55 25 61 24 | Sophie Boulila / Pierre Laurent | Melanie Sollid-Penton |
investors@eos-imaging.com | Tel.: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr | Ph: 646-536-7023 |
msollid@theruthgroup.com |
Page 1 of 1
|
distributed by
|
